Navigation Links
Ablation Technologies Market Expected to Reach USD 10.6 Billion Globally in 2020: Transparency Market Research
Date:8/7/2014

as led to the broader acceptance of the devices. Awareness and better healthcare infrastructure have also contributed towards growth of the market. During the forecasted period, the Asia-pacific market is expected to be the fasted growing market. Some of the prominent drivers for this market include increase in disposable income, government intervention to reform healthcare facilities and infrastructure developments. Growing trend for medical tourism in this region also uplifts the market for ablation technologies.

Some of the major players in the ablation technologies market include St. Jude Medical, Inc., Biosense Webster Inc., Medtronic, Inc., Covidien PLC, BSD Medical Corporation, Angiodynamics, Inc., and Boston Scientific Corp among other prominent players in the market.

The global ablation technologies market is segmented as follows:

  • Ablation Technologies Market, by Application 

    Cardiovascular

    Gynecology

    Pain Management

    Oncology

    Urology

    Ophthalmology

    Others

  • Ablation Technologies Market, by Technologies  

    Radiofrequency

  • Ablation Technologies Market, by Geography 

    North America

    Europe

    Asia-Pacific

    Rest of the World

Browse All Medical Devices Market Research Reports @ http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html

About Us  

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analys
'/>"/>

SOURCE http://www.transparencymarketresearch.com/
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
2. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
3. Ablation Devices Market to 2016 - (Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Cardiac, Cancer and Gynecology) - Global Market Forecast and Trends Analysis by Technology, Devices & Applications
4. MedWaves Inc.s Microwave Ablation Proves Effective in Destroying Thyroid Nodules in German Hospital Patient
5. GLP Preclinical Studies Demonstrate nContact Ablation Lesions Are Complete and Transmural
6. Radiofrequency Ablation Devices Market for Pain Management is Expected to Reach USD 1.0 Billion Globally in 2018: Transparency Market Research
7. SonaCare Medical Partners with University College London to Create Center of Excellence for HIFU Surgical Ablation Technology
8. Use Of Cryoablation For Treatment Of Breast Cancer Shows Promising Results
9. Pain Management Devices Market (Electrical Stimulators, Radiofrequency Ablation, Analgesic Pumps, Neurostimulation Devices) Is Expected to Reach USD 5.0 Billion Globally in 2018: Transparency Market Research
10. EPGL Medical Invents Smart Epidural Needle, Nerve Ablation And Trigger Point Treatment Devices
11. Competitive Activity In The Electrophysiology Mapping And Ablation Device Market Will Be Fueled By The Growing Focus On Atrial Fibrillation Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
(Date:9/2/2015)... -- Elekta, a global cancer management company, will ... 6:30-8:30 p.m., at Elekta,s North American headquarters in ... will feature Professional BMX athlete, Josh Perry , who ... Leksell Gamma Knife®, Elekta,s radiosurgery system for treating brain disorders. ... diagnosed in Georgia in 2015 and ...
(Date:9/2/2015)... Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCQB: GNBT) ... to implement a buccal cannabis co-development arrangement ... has been formalized. Generex and ... and Technology Licensing Agreement.  Pursuant to the ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 2Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 3Generex Announces Formalization of Buccal Cannabis Co-Development Plan 2Generex Announces Formalization of Buccal Cannabis Co-Development Plan 3
... , , INDIANAPOLIS, Nov. 16 ... Chairman, President and Chief Executive Officer John Lechleiter today presented ... check represents the contributions of Lilly,s U.S. employees and retirees ... funds were raised for the Central Indiana chapter and other ...
... , - Used during coronary angioplasty plus stenting, in ... new reversible blood thinner did not have a significantly ... all-cause mortality, heart attack and need for new procedures ... drug significantly lessened the risk for two pre-specified single ...
Cached Medicine Technology:Lilly Surpasses United Way 2009 Campaign Goal 2Lilly Surpasses United Way 2009 Campaign Goal 3American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 2American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 3
(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, a leading ... two leaders who will deliver keynote presentations at the upcoming Digital Healthcare Innovation ... Hotel in Boston. , Larry Renfro, CEO of Optum, will deliver the morning ...
(Date:9/2/2015)... ... 2015 , ... The Western Connecticut Health Network (WCHN) has ... to establish the Abraham and Mildred Goldstein Endowment Fund for Ovarian Cancer Research. ... known gynecologic oncologist Thomas J. Rutherford, MD, PhD as its network physician director ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... data collection, cloud analytics and workflow solutions today announced the September 2015 ... researchers to participate in interactive programs in which ERT scientists and partner ...
(Date:9/2/2015)... Waltham, MA (PRWEB) , ... September 02, 2015 ... ... often get swamped with a large stream of mixed documents that include EOBs, ... the various documents, while extracting the data needed to reconcile their billing, with ...
(Date:9/2/2015)... ... September 02, 2015 , ... Michael Elliot Media announces a ... plus-size actress as the primary love interest in the film. The campaign is being ... significantly affects how and what we think,” Michael Elliot, an award-winning screenwriter and CEO ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:Award-Winning Screenwriter Uses Crowdfunding Campaign to Change Hollywood’s Ideal of Beauty to Include PLUS-SIZE Women 2
... weight loss drugs are really safe, an analysis of previous ... was conducted. What// came to light was the lack of ... ,Two Canadian researchers, Raj Padwal and Sumit Majumdar of ... like sibutramine (Meridia), orlistat (Xenical) and rimonabant (Acomplia) are no ...
... new proposal released by Gov. Arnold Schwarzenegger recently, workers ... double benefit - to their// health and wealth. Employees ... be exempted from tax. ,The proposal is ... is reachable to the approximate 6.5 million Californians who ...
... towards understanding how the human brain learns to recognize ... of Technology, in 2003 launched a project to study ... Prakash" aims to study, identify and, treat, children who ... a lady born blind was studied by the professor, ...
... India plans to promote the development of public-private partnerships ... the National AIDS Control Programme (NACP-III) is likely to ... that approx. 80 per cent of the Indians seek ... per cent for inpatient care. ,A national ...
... diabetes mellitus (NODM) develops in certain patients following a liver ... to develop//, finds that all the risk factors can be ... tailored to the patient's risk ,They found the ... and hepatitis C infection (HCV) paired with the use of ...
... Prevention (CDC) Atlanta's Division of Tuberculosis Elimination feel that ... made TB tests mandatory for all foreign-born nationals, irrespective ... ,Tuberculosis can only be eradicated if all foreign-born ... treated for latent TB infection, they say. ...
Cached Medicine News:Health News:Latest Research on Visual Skills is an Eye Opener 2Health News:Risk Factors That Cause NODM After A Liver Transplant 2Health News:All Foreign-born Nationals In US To Be Tested For TB 2
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
... The DRS 2000, a uniquely intelligent system, ... its space saving, 2-level design. Up to 27 ... to give you the flexibility to tailor your ... lab. Two start stations allow for continuous loading; ...
... latest from the leader in automatic slide ... modern approach to slide staining, ending messy ... blood smears, bone marrow and other body ... Aerospray stainer becomes a superb cytocentrifuge with ...
Medicine Products: